Fucoidan from Sargassum autumnale Inhibits Potential Inflammatory Responses via NF-κB and MAPK Pathway Suppression in Lipopolysaccharide-Induced RAW 264.7 Macrophages.
N M LiyanageHyo-Geun LeeD P NagahawattaH H A C K JayawardhanaKyung-Mo SongYun-Sang ChoiYung Hyun ChoiMin-Cheol KangPublished in: Marine drugs (2023)
Fucoidans are sulfate-rich polysaccharides with a wide variety of beneficial biological activities. The present study aimed to highlight the anti-inflammatory activity of fucoidan from the brown seaweed Sargassum autumnale (SA) against lipopolysaccharide (LPS)-induced RAW 264.7 macrophage cells. Among the isolated fucoidan fractions, the third fraction (SAF3) showed a superior protective effect on LPS-stimulated RAW 264.7 cells. SAF3 inhibits nitric oxide (NO) production and expression of prostaglandin E-2 (PGE2) via downregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2) expression in LPS-induced RAW 26.7 cells. SAF3 treatment decreased pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 expression in LPS-induced cells. LPS stimulation activated NF-κB and MAPK signaling cascades in RAW 264.7 cells, while treatment with SAF3 suppressed them in a concentration-dependent manner. Existing outcomes confirm that SAF3 from S. autumnale possesses potent anti-inflammatory activity and exhibits good potential for application as a functional food ingredient or for the treatment of inflammation-related disorders.
Keyphrases
- lps induced
- inflammatory response
- induced apoptosis
- lipopolysaccharide induced
- nitric oxide
- signaling pathway
- nitric oxide synthase
- oxidative stress
- poor prognosis
- endoplasmic reticulum stress
- adipose tissue
- long non coding rna
- toll like receptor
- cell proliferation
- metabolic syndrome
- type diabetes
- anti inflammatory
- skeletal muscle
- human health
- combination therapy
- weight loss
- insulin resistance